TABLE 3

Lung function in study groups

Never- and ex-smokers with <10 pack-yearsNon-obstructive patients with ≥10 pack-yearsACOS: ≥10 pack-years FEV1/FVC <0.7p-value#
Subjects n1223234
Post bronchodilator
 FEV1 L2.74 (2.30–3.34)3.08 (2.34–3.60)2.32 (1.80–2.98)¶,+0.002
 FEV1 % pred93.0 (84.0–102.0)88.5 (81.0–95.0)75.0 (57.5–85.5)¶,+<0.001
 FEV1/FVC0.77 (0.72–0.81)0.78 (0.72–0.81)0.62 (0.54–0.67)¶,+<0.001
 FVC L3.65 (3.07–4.36)3.85 (3.04–4.80)3.92 (3.41–4.47)0.428
 FVC % pred99.0 (89.0–110.0)93.0 (82.5–105.0)98.5 (91.0–106.5)0.080
FEV1 reversibility§
 mL108.8±137.891.6±104.5135.6±149.90.404
 %4.2±5.53.2±3.76.7±7.7+0.034
FVC reversibility§
 mL23.9±150.352.5±148.2151.2±239.70.001
 %0.8±4.41.6±3.94.3±6.60.001

Data are presented as mean±sd, or median (interquartile range), unless otherwise stated. Statistically significant p-values are presented in bold. #: p-value across all groups; : as compared to group 1 (never- and ex-smokers with <10 pack-years), p<0.05; +: as compared to group 2 (non-obstructive patients with ≥10 pack-years), p<0.05; §: change from pre- to post-bronchodilator. ACOS: asthma–chronic obstructive pulmonary disease overlap syndrome; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.